Click on headlines below to download research
Solid start to 2017
aap Implantate | 18/05/2017
aap Implantate has announced a solid start to 2017 with Q1 trauma sales increasing by 30% to €2.9m and total sales up 23% to €3.1m, slightly…
Intention to raise equity to progress development
4SC | 17/05/2017
4SC has announced an updated development programme, to be funded by an equity fund-raising, which we expect in 2017. The proceeds from this will be used…
Steady progress
MagForce | 17/05/2017
MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer.…
SCLC data - subgroup analysis hints at benefit
Mologen | 16/05/2017
Top-line data from Mologen’s Phase II small cell lung cancer trial (IMPULSE) have been announced. Positive responses in two subgroups hint at a treatment-related…
Steady progress
MagForce | 15/05/2017
MagForce is moving forward with its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer.…
Q1 constant currency organic growth was 13%
GFT | 12/05/2017
GFT remains on target and thematic trends are broadly the same. Underlying Q1 revenue growth was solid at 13.3%, helped by 3% more days in the period,…
Funded to execute clinical development strategy
Medigene | 12/05/2017
Medigene recently announced a placing of €20.7m gross (issuing 1.96m new shares at €10.55) to intensify its R&D through the expansion of its…
On track for two filings by mid-2018
Paion | 12/05/2017
Paion has completed patient recruitment in its pivotal bronchoscopy study of its ultra-fast-acting sedative remimazolam. Results are likely by mid-2017…
Agreement reached
Evolva | 09/05/2017
EverSweet is due to be launched in 2018 following the recent, much-awaited collaboration agreement with Cargill. Evolva is due to participate in the JV…
Fund-raising to accelerate clinical programme
Medigene | 05/05/2017
Medigene has announced a placing of €20.7m gross (issuing 2m new shares at €10.55) to intensify its R&D through the expansion of its planned…
Value-add specialist
Grand City Properties | 25/04/2017
Grand City Properties (GCP) is a specialist residential real estate company investing in underperforming assets in major German urban centres. Its €4.9bn…
Becoming an increasingly prominent player
Medigene | 24/04/2017
Medigene is well funded (FY16 cash €52.6m) to advance both its DC vaccine programmes and TCR programme. We expect a number of important milestones…
Rapid start to DBAG Fund VII’s investment period
Deutsche Beteiligungs | 21/04/2017
Deutsche Beteiligungs (DBAG) has continued into FY17 the strong pace of portfolio activity achieved in the previous two financial years, with c €63m…
Termination of coverage
Epigenomics | 13/04/2017
Edison Investment Research is terminating coverage on Epigenomics (ECX). Please note you should no longer rely on any previous research or estimates for…
Termination of coverage
Ifa Systems | 11/04/2017
Edison Investment Research is terminating coverage on Ifa Systems (IS8). Please note you should no longer rely on any previous research or estimates for…
Time to capitalise on its core focus - trauma
aap Implantate | 06/04/2017
aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results…
Consolidation in FY17, acceleration in FY18
GFT | 31/03/2017
While GFT reported FY16 revenues and EBITDA slightly ahead of our forecasts, the shares fell in response to unexpectedly weak FY17 guidance and higher…
A streamlined focus moving forward
4SC | 30/03/2017
2016 was an important year for 4SC as it launched its potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL. In addition,…
Positive data in high-risk patients
Paion | 27/03/2017
Paion has taken an important step towards its goal of US approval for its ultra-fast-acting sedative, remimazolam with the announcement of positive top…
Xadago receives FDA approval in PD
Newron Pharmaceuticals | 22/03/2017
Newron and its partners Zambon and US WorldMeds have announced that the FDA has approved Xadago (safinamide) for Parkinson’s disease (PD) patients…
On track to file in US and Japan by mid-2018
Paion | 20/03/2017
Paion has successfully accelerated recruitment in the confirmatory pivotal bronchoscopy study of its ultra-fast-acting sedative remimazolam in procedural…
Termination of coverage
Evotec | 19/03/2017
Edison Investment Research is terminating coverage on Evotec (EVT). Please note you should no longer rely on any previous research or estimates for this…
Hitting form
Borussia Dortmund | 16/03/2017
Although in transition after high-profile player departures, Borussia Dortmund (BVB) continues to compete well on all fronts. Its financial performance…
Headroom improves
Evolva | 16/03/2017
Evolva has secured equity financing of up to CHF30m. This is a fully flexible arrangement with relatively good terms, which if drawn down in full would…
Marching into 2017
Newron Pharmaceuticals | 13/03/2017
We anticipate that the sales and pipeline progression made by Newron in 2016 will be cemented further in 2017/18. A critical catalyst remains the US Xadago…